Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.
The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.
A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found.
The chemotherapy drug cisplatin is an effective cancer treatment for many children with cancer, but unfortunately it can cause permanent hearing loss.
Scientists at St. Jude Children's Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL).
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.
With advances in medical science driving progress against childhood brain tumors, today three out of four young patients survive at least five years beyond diagnosis. However, the outcomes look grim when malignant cells spread, or metastasize.
Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A discovery by University of Queensland pain researchers may allow some future cancer patients, including children with leukemia, to avoid their chemotherapy's worst and most debilitating side effects.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP—the standard treatment regimen.
Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases.
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
Through genetic sequencing and targeted treatment, researchers from Children's Hospital of Philadelphia have resolved a severe lymphatic disorder in a young woman with kaposiform lymphangiomatosis (KLA), a complex and rare disorder that causes lymphatic vessels around the heart and lung to leak fluid, causing breathing difficulties, infections, and often death.
A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.
A team of scientists from Peter the Great St.Petersburg Polytechnic University together with their colleagues developed a method of targeted drug delivery to cancer cells.
A team of scientists from Peter the Great St.Petersburg Polytechnic University together with their colleagues developed a method of targeted drug delivery to cancer cells. The discovery is based on the use of mesenchymal stem cells and microcapsules made of polymeric compounds.
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.